By Dean Seal
Shares of Talaris Therapeutics jumped after the company said it would combine with Tourmaline Bio in an all-stock merger deal.
The stock was up 23.2% at $2.71 in early trading. The stock is down 65% over the past 12 months but has more than doubled since the start of the year.
The two companies said Thursday morning that they would combine into a single entity operating under the Tourmaline Bio banner that will focus on advancing Tourmaline's treatment for thyroid eye disease and atherosclerotic cardiovascular disease.
Talaris holders are expected to receive about $3.43 a share, including a cash dividend of up to about $64.8 million.
The deal is expected to close in the fourth quarter, pending the approval from stockholders of both companies.
Talaris said in February that it would explore strategic alternatives and slash a third of its staff after development on its lead drug candidate in kidney transplants was scrapped.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 22, 2023 10:16 ET (14:16 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.